Mymd Pharmaceuticals (NASDAQ:QCLS) Rating Lowered to “Sell” at Wall Street Zen

Mymd Pharmaceuticals (NASDAQ:QCLS) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday.

Separately, Weiss Ratings began coverage on Mymd Pharmaceuticals in a research note on Wednesday, May 13th. They issued a “sell (e+)” rating for the company. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Mymd Pharmaceuticals presently has an average rating of “Sell”.

Mymd Pharmaceuticals Price Performance

QCLS stock opened at $2.92 on Friday. Mymd Pharmaceuticals has a twelve month low of $2.50 and a twelve month high of $12.24. The firm has a market capitalization of $12.18 million, a P/E ratio of -0.14 and a beta of 2.16. The stock’s 50 day moving average is $3.55.

Mymd Pharmaceuticals (NASDAQ:QCLS) last posted its quarterly earnings results on Friday, May 15th. The company reported ($0.19) earnings per share (EPS) for the quarter.

About Mymd Pharmaceuticals

MyMD Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for immune-related and other serious diseases. The company has worked on product candidates designed to address conditions involving inflammation, immune system dysfunction, and age-related disease processes.

The company’s pipeline has included drug development programs in areas such as autoimmune and inflammatory disorders, with an emphasis on advancing compounds through preclinical and clinical evaluation.